What is Neuronetics's market cap?

Neuronetics (STIM) has a market capitalization of $126.0M and trades on NASDAQ.

What is Neuronetics's revenue and profitability?

Neuronetics generated $151.6M in trailing twelve-month revenue with a net loss of $37.1M, representing a net margin of -24.5%. Gross margin stands at 48.0%, with free cash flow of -$14.3M. These figures are based on the Q1 2026 filing.

Who are Neuronetics's competitors?

Neuronetics's key competitors include Minerva Neurosciences, Inc, Nexalin Technology, Inc. Common Stock, NRX Pharmaceuticals, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Neuronetics partner with?

Neuronetics's notable partners include Janssen Pharmaceuticals, Madryn Asset Management, LP.

What subsidiaries does Neuronetics have?

Neuronetics's subsidiaries include Greenbrook TMS Inc..

Where is Neuronetics headquartered?

Neuronetics is headquartered in United States of America and employs approximately 202 people. It has been publicly traded since 2018.

Neuronetics

STIM

Neuronetics is a global leader in neuroscience and mental health services, specializing in non-invasive treatments for psychiatric disorders.

Market cap

$125.95M-57.1%

Revenue$151.6M+69.5%

Net income-$37.1M+23.5%

Free cash flow-$14.3M+61.7%

EPS (diluted)-$0.54+59.1%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 5, 2026

Revenue$34.5MBeat by $286.0K EPS-$0.16Beat by $0.01

Read the full report

Next report

Aug 4, 2026 (In 6 days)

Revenue estimate$40.2M

EPS estimate-$0.11

Financials

Q1 2026

Income statement

See full

Revenue$34.5M+7.8%

Gross profit$16.2M+2.6%

Operating income-$9.0M+18.3%

Net income-$10.8M+14.9%

EPS (diluted)-$0.16+23.8%

Balance sheet

See full

Cash & equivalents$13.2M-34.7%

Total debt$85.4M+3.5%

Total equity$13.3M-62.6%

Total assets$125.4M-11.7%

Cash flow

See full

Operating cash flow-$9.4M+44.6%

CapEx$197.0K-10.0%

Free cash flow-$9.6M+44.1%

Valuation & ratios

Valuation

See full

Market cap$125.95M-57.1%

Enterprise value$198.13M-46.2%

P/S0.8×-1.9×

Profitability

See full

Gross margin48%-15.6pp

Operating margin-19.4%-6.9pp

Net margin-24.5%-8.7pp

FCF margin-9.4%-4.1pp

Returns & leverage

See full

Return on equity-152.4%-1.4pp

Debt / equity6.4×+4.1×

Current ratio1.7×-0.8×

Segments

By product

See full

Clinic Revenue$21.5M+15.4%

Service$21.5M+15.4%

Treatment Sessions$9.2M-5.3%

Neuro Star Advanced Therapy System$3.2M+7.9%

By segment

See full

Clinical Services$21.5M+15.4%

Medical Device$12.9M-2.9%

By geography

See full

Non Us$228.0K-53.7%

Competitors

By market cap

LifeStance Health Group$4.2B+156%

LBR

LB Pharmaceuticals Inc Common Stock$997.4M—

Minerva Neurosciences$195.9M+1,234%

NRX Pharmaceuticals, Inc.$155.4M+172%

Neuronetics$126.0M-57.9%

BioXcel Therapeutics, Inc.$26.8M+160%

Cyclerion Therapeutics$15.2M+53.1%

Nexalin Technology, Inc.$9.7M-49.9%

By revenue growth

Neuronetics+69.5%

LifeStance Health Group+16.5%

By net margin

LifeStance Health Group1.55%+3.8pp

Neuronetics-24.48%+29.8pp

Profile

Neuronetics is a global leader in neuroscience and mental health services, specializing in non-invasive treatments for psychiatric disorders. The company's core value proposition centers on its proprietary NeuroStar Advanced Therapy System, which utilizes transcranial magnetic stimulation (TMS) to treat major depressive disorder and obsessive-compulsive disorder. Through its wholly owned subsidiary, Greenbrook, the company also operates a network of outpatient mental health service centers providing TMS and esketamine nasal spray treatments.

Competitive position

The company is a market leader in TMS therapy with the largest clinical data set in the industry and a significant footprint of company-operated treatment centers.

GeographiesUnited States, Japan, European Union

Customer segmentsSpecialized medical practices, Individual patients, Healthcare providers

Business modelCapital equipment sales, Razor-and-blade (recurring treatment sessions), Direct-to-consumer healthcare services, Subscription SaaS (practice management)

SuppliersMedical component manufacturers, Pharmaceutical suppliers (esketamine), Software developers

CustomersPsychiatric clinics, Hospitals, Insured patients, Federal healthcare programs

CountryUnited States of America

Listed2018

Employees202.0

CEODaniel L. Reuvers

SectorHealthcare

IndustryMedical - Diagnostics & Research

Websiteneurostar.com

FilingsSEC EDGAR

Ask your AI about Neuronetics.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Neuronetics's market cap?: Neuronetics (STIM) has a market capitalization of $126.0M and trades on NASDAQ.
What is Neuronetics's revenue and profitability?: Neuronetics generated $151.6M in trailing twelve-month revenue with a net loss of $37.1M, representing a net margin of -24.5%. Gross margin stands at 48.0%, with free cash flow of -$14.3M. These figures are based on the Q1 2026 filing.
Who are Neuronetics's competitors?: Neuronetics's key competitors include Minerva Neurosciences, Inc, Nexalin Technology, Inc. Common Stock, NRX Pharmaceuticals, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Neuronetics partner with?: Neuronetics's notable partners include Janssen Pharmaceuticals, Madryn Asset Management, LP.
What subsidiaries does Neuronetics have?: Neuronetics's subsidiaries include Greenbrook TMS Inc..
Where is Neuronetics headquartered?: Neuronetics is headquartered in United States of America and employs approximately 202 people. It has been publicly traded since 2018.